TRANSFORM II Trial Finds Sirolimus-Coated Balloon Comparable to Drug-Eluting Stents at One Year
The TRANSFORM II trial, involving 1,842 patients across 53 centers in 11 countries, found that the MagicTouch Sirolimus-Coated Balloon (SCB) is non-inferior to everolimus-eluting stents (EES) for treating de novo coronary artery disease at 12 months. Target Lesion Failure rates were similar between SCB (2.1%) and EES (2.4%) groups. The study included patients with complex conditions such as acute coronary syndrome, diabetes, and high bleeding risk, and results were presented at TCT 2026 and published in The Lancet.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 44/100.
Outlets measured: thetribune, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 2 Nov, 12:15 pm. Other outlets followed.